Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional networkopen access
- Authors
- Chae, Hee-Sung; You, Byoung Hoon; Kim, Dong-Yeop; Lee, Hankyu; Ko, Hyuk Wan; Ko, Hyun-Jeong; Choi, Young Hee; Choi, Sun Shim; Chin, Young-Won
- Issue Date
- 30-Apr-2018
- Publisher
- NATURE PUBLISHING GROUP
- Citation
- SCIENTIFIC REPORTS, v.8, no.1
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- SCIENTIFIC REPORTS
- Volume
- 8
- Number
- 1
- URI
- https://scholarworks.dongguk.edu/handle/sw.dongguk/9560
- DOI
- 10.1038/s41598-018-24935-6
- ISSN
- 2045-2322
- Abstract
- Whole-transcriptome analysis and western blotting of sauchinone-treated HepG2 cells demonstrated that sauchinone regulated genes relevant to cholesterol metabolism and synthesis. In particular, it was found that the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) was downregulated, and the expression of low density lipoprotein receptor (LDLR) was upregulated in sauchinone-treated HepG2 cells. Consequently, LDL-cholesterol (LDL-C) uptake was increased. As a transcriptional regulator of PCSK9 expression, sterol regulatory elements binding protein-2 (SREBP-2) was proposed by transcriptome analysis and western blotting. Oral administration of sauchinone increased hepatic LDLR through PCSK9 inhibition in obese mice and showed the reduced serum LDL-C levels and downstream targets of SREBP-2. Thus, it is evident that sauchinone reduces hepatic steatosis by downregulating the expression of hepatic PCSK9 via SREBP-2.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > Department of Pharmacy > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.